Valuation: CareDx, Inc.

Market Cap 2.78B 2.43B 2.29B 2.08B 3.9B 267B 3.92B 27.47B 10.6B 136B 10.46B 10.23B 437B P/E 2026 *
25.4x
P/E 2027 * 119x
Enterprise Value 2.78B 2.43B 2.29B 2.08B 3.9B 267B 3.92B 27.47B 10.6B 136B 10.46B 10.23B 437B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 5.31x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week+7.10%
Current month+7.42%
1 month+14.56%
3 months+105.61%
6 months+213.88%
Current year+185.72%
1 week 51.73
Extreme 51.7301
55.16
1 month 46.69
Extreme 46.6879
55.16
Current year 15.56
Extreme 15.56
55.16
1 year 13.95
Extreme 13.95
55.16
3 years 4.8
Extreme 4.8
55.16
5 years 4.8
Extreme 4.8
75.92
10 years 0.76
Extreme 0.76
99.83
Manager TitleAgeSince
Chief Executive Officer 46 2024-04-14
Director of Finance/CFO 56 2026-02-25
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 68 2021-10-31
Chairman 59 2019-12-31
Director/Board Member 70 2014-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/26 Tax

Executive/Senior Manager

-6,688 0.0129%
9/12/26 Tax

Chief Financial Officer

-8,220 0.0159%
8/5/26 Sell

General Counsel

-2,688 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%+7.10%+268.95%+586.61% 2.78B
+2.30%+19.19%+400.00%+95.24% 4.64B
+0.21%+18.22%+114.15%+452.32% 4.57B
-1.91%-2.63%+16.67%+70.57% 3.2B
+6.41%+10.68%-21.68%-25.15% 2.27B
+10.59%+13.36%+53.68% - 1.84B
+0.30%+7.13%+27.07%+57.21% 1.11B
-4.13%+6.74%+158.15%-30.37% 1.04B
-3.88%-4.48%-19.56%+36.87% 568M
+2.98%+4.96%-32.85%-23.42% 519M
Average +1.20%+7.56%+96.46%+135.54% 2.25B
Weighted average by Cap. +1.45%+10.64%+150.67%+210.15%

Financials

2026 *2027 *
Net sales 495M 432M 408M 370M 694M 47.5B 696M 4.88B 1.88B 24.15B 1.86B 1.82B 77.71B 524M 457M 431M 392M 734M 50.28B 737M 5.17B 1.99B 25.56B 1.97B 1.92B 82.25B
Net income 118M 103M 96.8M 87.9M 165M 11.28B 165M 1.16B 447M 5.74B 442M 432M 18.45B 20.73M 18.08M 17.07M 15.5M 29.04M 1.99B 29.16M 204M 78.9M 1.01B 77.88M 76.15M 3.25B
Net Debt - -
Logo CareDx, Inc.
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Employees
763
Date Price Change Volume
26-09-18 US$53.83 -0.83% 1,384,015
26-09-17 US$54.28 +1.36% 806,701
26-09-16 US$53.55 +1.73% 846,283
26-09-15 US$52.64 +0.52% 950,020
26-09-14 US$52.37 +4.20% 795,534
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
53.83USD
Average target price
54.14USD
Spread / Average Target
+0.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDNA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!